NI 301

Drug Profile

NI 301

Alternative Names: NI-301

Latest Information Update: 26 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neurimmune Therapeutics
  • Class Cardiovascular therapies; Monoclonal antibodies
  • Mechanism of Action Prealbumin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Amyloid polyneuropathy; Neurological disorders

Highest Development Phases

  • Preclinical Cardiomyopathies; Neurological disorders

Most Recent Events

  • 26 Apr 2017 NI 301 is available for licensing as of 26 Apr 2017. http://www.neurimmune.com/company/about-neurimmune.html
  • 26 Apr 2017 Preclinical trials in Cardiomyopathy in Switzerland (Neurimmune pipeline)
  • 26 Apr 2017 Preclinical trials in Neurological disorders in Switzerland (Neurimmune pipeline)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top